PERIPHAGEN

Periphagen is a biopharmaceutical company focused on the development of herpes simplex virus type I (HSV-1) as a gene therapy vector. Our primary focus is the use of HSV-1 vectors for neurologic disease but we also have extensive experience and HSV-1 vector technology available for other indications... We believe that the best way to treat nervous system diseases is to directly target neurons. We have been developing HSV-1 vectors for more than 25 years and have developed a replication defective HSV-1 vector platform called "Neuronal Therapeutics" (NET) for delivery of tissue specific gene expression in sensory neurons from a simple skin administration, allowing for unparalleled treatment specificity and substantially reduced systemic adverse effects.

Also known as: PeriphaGen, Inc.

Primary location: Pittsburgh United States